Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Cameron

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Clinical Pharmacology and Therapeutics|August 15, 2001
A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virusK Gallicano, Y Khaliq, G Carignan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 13, 2003
A review of low-dose ritonavir in protease inhibitor combination therapyC L Cooper, R P G van Heeswijk, K Gallicano, et al.
Methods in Molecular Medicine|March 8, 2011
Quantification of HIV-1 RNA in Dried Plasma Spots (DPS) : A Field Approach to Therapeutic MonitoringS A Cassol, F Diaz-Mitoma, R Pilon, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 1, 1988
The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 2. Mechanisms involved in the actions and interactions of the convulsant bemegride and its hypnotic homologue 3-methyl-3-n-butylglutarimideC I Arblaster, D W Cameron, Y Lavi, et al.
Methods and Findings in Experimental and Clinical Pharmacology|August 1, 1987
The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 1: 3,3-Diakylglutarimide homologues and related drugsC I Arblaster, D W Cameron, Y Lavi, et al.
British Journal of Clinical Pharmacology|August 1, 1993
Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patientsK Gallicano, J Sahai, E Ormsby, et al.
Antimicrobial Agents and Chemotherapy|September 2, 2009
Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteersC J L la Porte, J P Sabo, L Béïque, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 yearsC L Cooper, J B Angel, I Seguin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 4, 2012
A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive proteinG G Alvarez, E Sabri, D Ling, et al.
AIDS Research and Human Retroviruses|August 26, 1999
Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1betaD Kumar, K Parato, A Kumar, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Clinical Pharmacology and Therapeutics|August 15, 2001
A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virusK Gallicano, Y Khaliq, G Carignan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 13, 2003
A review of low-dose ritonavir in protease inhibitor combination therapyC L Cooper, R P G van Heeswijk, K Gallicano, et al.
Methods in Molecular Medicine|March 8, 2011
Quantification of HIV-1 RNA in Dried Plasma Spots (DPS) : A Field Approach to Therapeutic MonitoringS A Cassol, F Diaz-Mitoma, R Pilon, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 1, 1988
The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 2. Mechanisms involved in the actions and interactions of the convulsant bemegride and its hypnotic homologue 3-methyl-3-n-butylglutarimideC I Arblaster, D W Cameron, Y Lavi, et al.
Methods and Findings in Experimental and Clinical Pharmacology|August 1, 1987
The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 1: 3,3-Diakylglutarimide homologues and related drugsC I Arblaster, D W Cameron, Y Lavi, et al.
British Journal of Clinical Pharmacology|August 1, 1993
Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patientsK Gallicano, J Sahai, E Ormsby, et al.
Antimicrobial Agents and Chemotherapy|September 2, 2009
Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteersC J L la Porte, J P Sabo, L Béïque, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 yearsC L Cooper, J B Angel, I Seguin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 4, 2012
A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive proteinG G Alvarez, E Sabri, D Ling, et al.
AIDS Research and Human Retroviruses|August 26, 1999
Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1betaD Kumar, K Parato, A Kumar, et al.
Pageof 8